Pipeline
CagriSema: what it is, where it stands, and what the trial data actually show
Novo Nordisk's CagriSema achieved ~23% weight loss in Phase 3 trials but failed to demonstrate non-inferiority to tirzepatide in a head-to-head test. An NDA is under FDA review. Here's what patients following the pipeline need to know.
3 min read · Updated 2026-05-25
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Key takeaways
- CagriSema combines cagrilintide 2.4 mg (an amylin analogue) with semaglutide 2.4 mg in a once-weekly injectable
- In the REDEFINE 4 head-to-head trial (84 weeks), CagriSema achieved 20.2% weight loss vs tirzepatide's 23.6% (treatment-regimen estimand) — and failed to demonstrate non-inferiority
- On-treatment REDEFINE analyses showed approximately 23% weight loss for CagriSema
- Novo Nordisk submitted an NDA to the FDA; a decision is expected in 2026; the drug is not approved as of May 2026
- Do not treat CagriSema as currently available
What CagriSema is — and how it works differently
CagriSema is a fixed-ratio combination: cagrilintide 2.4 mg plus 2.4 mg, administered as a once-weekly .
Semaglutide is well-known — it's the active ingredient in Wegovy (approved for weight management) and Ozempic (approved for ). Cagrilintide is a long-acting amylin analogue. Amylin is a hormone co-secreted with from the ; it signals satiety, slows , and reduces secretion. A short-acting amylin analogue, pramlintide (Symlin), is for use alongside insulin in type 1 and type 2 diabetes, but is not used for weight management.
The rationale for combining them: targeting two different satiety pathways simultaneously. Semaglutide acts through ; cagrilintide acts through amylin receptors. The combination was hypothesized to produce additive or synergistic weight loss effects.
What the REDEFINE trials found
The REDEFINE program was Novo Nordisk's series for CagriSema. In on-treatment or completer analyses from the REDEFINE trials, CagriSema achieved approximately 23% weight loss — a figure Novo Nordisk highlighted in its communications.
That number comes from analyses that account for adherence and completers. Different statistical approaches (called estimands) produce somewhat different numbers when accounting for participants who discontinued or deviated from the protocol — which is important context when comparing results across drugs and trials.
The REDEFINE 4 head-to-head: what non-inferiority means and why it matters
REDEFINE 4 (NCT06131437) was an 84-week, open-label trial comparing CagriSema to 15 mg in 809 people with and comorbidities.
The primary endpoint was non-inferiority: Novo Nordisk was not trying to show CagriSema was better than tirzepatide — only that it was not meaningfully worse. That bar was not met.
Using the treatment-regimen estimand — which accounts for all participants regardless of adherence: CagriSema produced 20.2% weight loss vs tirzepatide's 23.6% at 84 weeks. The difference was statistically significant in tirzepatide's favor.
As STAT News reported in February 2026, the gap is approximately 3.4 percentage points in tirzepatide's favor. This does not mean CagriSema is not a useful drug — 20.2% average weight loss is a clinically meaningful result. But it does mean CagriSema enters a competitive market having demonstrated inferiority to the current best-performing approved drug in this trial.
Where the FDA review stands
Novo Nordisk submitted an NDA for CagriSema to the FDA in 2026. A decision is expected this year, though the agency has not confirmed a PDUFA date in publicly available sources as of May 2026.
NDA review doesn't guarantee approval. The FDA will evaluate safety, efficacy, and manufacturing quality independently. Given the REDEFINE 4 non-inferiority failure, what clinical differentiation Novo Nordisk argues — mechanism, side effect profile, specific patient population — will factor into the regulatory discussion.
CagriSema is not approved as of May 2026. It is not available by prescription. Do not treat it as a current option.
What remains uncertain
The FDA's timeline and outcome are uncertain. The drug could be approved, could receive a Complete Response Letter requesting additional data, or could be rejected. Long-term cardiovascular outcomes data for CagriSema are not available.
Whether the amylin pathway targeting in CagriSema produces cardiometabolic benefits distinct from semaglutide alone is an open research question. How CagriSema would be priced and covered relative to tirzepatide and semaglutide, if approved, is unknown.
Questions to ask your clinician
- When the FDA makes a decision on CagriSema, is it something we should consider for my situation?
- What would distinguish CagriSema from tirzepatide or semaglutide for my specific profile?
- Where should I follow the FDA approval process to stay informed?
Where to follow the pipeline
- Novo Nordisk investor relations: novonordisk.com
- FDA drug approval database: accessdata.fda.gov
- ClinicalTrials.gov, REDEFINE 4 (NCT06131437)
Check back with your prescriber when the FDA makes a decision on CagriSema. Your clinician can tell you whether it might be an option for your situation when — and if — it becomes available.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.